Provision of Diagnostic and Therapeutic Complementary Means Services - Oncotype DX Genomic Test

This tender concerns the provision of diagnostic and therapeutic complementary means services, specifically focusing on the Oncotype DX genomic test. The procurement aims to secure specialized services essential for cancer diagnosis and treatment planning. The Oncotype DX test is a molecular diagnostic tool used to assess the likelihood of cancer recurrence and the potential benefit of chemotherapy in early-stage breast cancer patients. By analyzing the genetic expression of a tumor, this test provides crucial information that helps oncologists make more personalized and effective treatment decisions, potentially avoiding unnecessary chemotherapy for some patients while identifying those who would benefit most. The service provider will be expected to deliver comprehensive support, including sample collection, laboratory analysis, and reporting of results, adhering to strict quality and turnaround time standards. This initiative underscores a commitment to advancing precision medicine in oncology, ensuring patients receive the most appropriate and evidence-based care. The scope of services is critical for enhancing diagnostic accuracy and optimizing therapeutic strategies within the healthcare sector, contributing to improved patient outcomes and efficient resource allocation in cancer treatment.

This is a services contract in the health and medical services, Research and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 137,700.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the health and medical services sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. This contract has already been awarded. The information is published for transparency and market intelligence purposes.